### [Bagchi and Haidar et al. Page 521][1] In some colorectal cancer (CRC) patients who develop resistance to cetuximab, tumors have acquired somatic mutations that map to the cetuximab epitope, blocking antibody binding. Bagchi, Haidar and colleagues show that necitumumab, another FDA approved

中文翻译：

---

本期要点

### [Bagchi和Haidar等。Page 521] [1]在一些对西妥昔单抗产生耐药性的结直肠癌（CRC）患者中，肿瘤获得了映射到西妥昔单抗表位的体细胞突变，从而阻断了抗体的结合。Bagchi，Haidar及其同事表明，另一种FDA批准的necitumumab